Based on CASPAR (The Classification Criteria for Psoriatic Arthritis) criteria, it is estimated that it occurs in up to 30% of patients with psoriasis (PsO) and that this progress occurs between 5–10 years after the onset of PsO. 3–5 Currently, there is no consensus on prevalence data for this disease. 1, 2 A great number of patients with PsA have progressive joint damage, reduced life expectancy, and increasing disability, which is related with a substantial reduction in quality of life. Psoriatic arthritis (PsA) is a common inflammatory disease affecting 1–3% of the population.
